Monday June 26th 2017

Archive for January, 2011

Doctor Challenges Cause Of MS And Treatment

Doctor Challenges Cause Of MS And Treatment

One day 7 years ago, after a long walk with his dog along the Hudson River in Manhattan, Marc Stecker noticed he was limping. Not long after, he was diagnosed with multiple sclerosis. “Fast forward now, and my entire right side is pretty much paralyzed and my left [Read More]

Newfoundlander Praises Zamboni Procedure

Newfoundlander Praises Zamboni Procedure

A Newfoundland man suffering from multiple sclerosis says his life has changed dramatically since having the so-called liberation treatment. Mark Lane travelled abroad to have the Zamboni Procedure late last year. The quick treatment opens-up blockages in neck veins. Lane [Read More]

MS patient gets ‘liberation’ therapy abroad, struggles to find followup care at home

MS patient gets ‘liberation’ therapy abroad, struggles to find followup care at home

A Saskatchewan man suffering from multiple sclerosis who travelled abroad to receive the controversial “liberation” therapy says he had difficulty getting followup care in Canada, leading him to seek treatment in the United States. Watson McGregor of Rosetown, [Read More]

 Page 1 of 5  1  2  3  4  5 »

Latest Topics

Are static and functional balance abilities related in individuals with Multiple Sclerosis? – Pau M, Porta M, Coghe G, Corona F, Pilloni G, Lorefice…

Are static and functional balance abilities related in individuals with Multiple Sclerosis? – Pau M, Porta M, Coghe G, Corona F, Pilloni G, Lorefice…

BACKGROUND: In people with Multiple Sclerosis (pwMS), balance assessment is essential in estimating the risk of falls, [Read More]

CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis

CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis

The European Medicines Agency ’ s Committee for Medicinal Products for Human Use recommends approval of cladribine to [Read More]

Germany’s Merck gets EU backing for oral MS drug

Germany’s Merck gets EU backing for oral MS drug

FRANKFURT (Reuters) - Germany's Merck KGaA has won a key recommendation to become a late entrant to the market for oral [Read More]

New data at EAN show Roche ’s OCREVUS (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary…

New data at EAN show Roche ’s OCREVUS (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary…

Roche announced today that new post-hoc analyses from the OCREVUS ™ (ocrelizumab) Phase III clinical trial programme [Read More]

MS Society Hosts Joint Congressional Briefing on the Value of Rehabilitation

MS Society Hosts Joint Congressional Briefing on the Value of Rehabilitation

/About-the-Society/News/Society-Hosts-Joint-Congressional-Briefing-on-the [Read More]